SCHEMBL261589

SCHEMBL261589

CCN1C(=O)c2ccc(Oc3cccc4c3C(=O)N(CC)C4=O)cc2C1=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.71
SMN1; SMN2 Q16637 2/20 0.71
KMT2A Q03164 6/20 0.51
MEN1 O00255 5/20 0.45
ALDH1A1 P00352 5/20 0.45
CYP1B1 Q16678 2/20 0.45
KDM4E B2RXH2 2/20 0.45
HTT P42858 2/20 0.45
USP2 O75604 1/20 0.45
ATM Q13315 1/20 0.45
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45
LPAR3 Q9UBY5 2/20 0.44
LPAR1 Q92633 1/20 0.44
HSD17B10 Q99714 2/20 0.44
MAPK1 P28482 1/20 0.44
MAPT P10636 1/20 0.44
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22215822 0.83 TDP1 (0.67) TDP1SMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL3822964 0.82 SMN1; SMN2 (0.61) TDP1SMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL260975 0.78 SMN1; SMN2 (0.57) TDP1SMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL12235607 0.78 CYP1B1 (0.53) TDP1SMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL15333870 0.78 CYP1B1 (0.46) TDP1SMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL19499368 0.77 ALDH1A1 (0.59) TDP1SMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL624642 0.77 CYP1B1 (0.45) TDP1SMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL22215847 0.76 TDP1 (0.57) TDP1SMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL13928043 0.76 ALDH1A1 (0.57) TDP1KMT2AMEN1ALDH1A1KDM4E
SCHEMBL21348853 0.74 KMT2A (0.57) TDP1SMN1; SMN2KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097375-B1 METHOD FOR PURIFYING BISIMIDES SABIC INNOVATIVE PLASTICS IP (NL) 2013-04-24 EP disclosed
EP-2089348-B1 METHOD FOR MAKING POLYETHERIMIDES SABIC INNOVATIVE PLASTICS IP (NL) 2013-02-20 EP disclosed
US-8134016-B2 Method for purifying dianhydrides SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2012-03-13 US disclosed
EP-2094691-B1 METHOD FOR PURIFYING DIANHYDRIDES SABIC INNOVATIVE PLASTICS IP (NL) 2011-05-25 EP disclosed
EP-2097375-A1 METHOD FOR PURIFYING BISIMIDES Sabic Innovative Plastics IP B.V. (NL) 2009-09-09 EP disclosed
EP-2094691-A1 METHOD FOR PURIFYING DIANHYDRIDES Sabic Innovative Plastics IP B.V. (NL) 2009-09-02 EP disclosed
EP-2089348-A1 METHOD FOR MAKING POLYETHERIMIDES Sabic Innovative Plastics IP B.V. (NL) 2009-08-19 EP disclosed
US-20080319210-A1 METHOD FOR PURIFYING DIANHYDRIDES SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2008-12-25 US disclosed
US-7446214-B2 Method for purifying oxybisphthalic anhydrides SABIC INNOVATIVE PLASTICS IP B.V. (US) 2008-11-04 US disclosed
US-7411032-B2 Method for making polyetherimides SABIC INNOVATIVE PLASTICS IP B.V. (US) 2008-08-12 US disclosed
US-7408070-B2 Method for purifying bisimides SABIC INNOVATIVE PLASTICS IP B.V. (US) 2008-08-05 US disclosed
WO-2008063206-A1 METHOD FOR MAKING POLYETHERIMIDES SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2008-05-29 WO disclosed
WO-2008063208-A1 METHOD FOR PURIFYING BISIMIDES SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2008-05-29 WO disclosed
WO-2008063207-A1 METHOD FOR PURIFYING DIANHYDRIDES SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2008-05-29 WO disclosed
US-20070073035-A1 Method for making polyetherimides GENERAL ELECTRIC COMPANY (US) 2007-03-29 US disclosed
US-20070073063-A1 Method for purifying bisimides GENERAL ELECTRIC COMPANY (US) 2007-03-29 US disclosed
US-20070073066-A1 Method for purifying dianhydrides GENERAL ELECTRIC COMPANY (US) 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070073063-A1 Method for purifying bisimides FHIT, PBRM1, TNS4 TDP1 2431/4885SMN1; SMN2 1842/4885KMT2A 363/4885
US-20080319210-A1 METHOD FOR PURIFYING DIANHYDRIDES AQP4, TRRAP, GYPA TDP1 1104/4885SMN1; SMN2 2824/4885KMT2A 266/4885
US-20070073066-A1 Method for purifying dianhydrides AQP4, TRRAP, GYPA TDP1 1104/4885SMN1; SMN2 2824/4885KMT2A 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.